Tuesday, April 18, 2006

Interesting Argument on Private Equity Fees (Financial Times)

The Financial Times makes a pretty compelling argument on the state of the fee structure at private equity firms.


At 5:49 AM, Anonymous Anonymous said...

Teva's long-held practice is to only pursue transactions that fit our long-term strategy of delivering profitable growth and enhancing our global leadership position while meeting our stringent financial criteria. While Merck's generics business would have been a strategic fit for Teva, the terms of this opportunity did not fully meet our San Diego investment criteria "


Post a Comment

Links to this post:

Create a Link

<< Home